Back to top

Analyst Blog

Leading heart pump maker HeartWare International (HTWR - Snapshot Report) recently revealed that it has strengthened its HeartWare Ventricular Assist System portfolio in Europe with the CE Mark extension for long-term use in patients susceptible to fatal heart failure. The company has also published the U.S. clinical results of ADVANCE, an Investigational Device Exemption (“IDE”) study, designed to test the system as a bridge to heart transplantation for advanced heart failure patients.

The expanded CE Mark label followed the success of the international trial, which resulted in high survival rates of critically ill patients and also the extended usage of ventricular assist devices (“VAD”) in Europe.  

The results of the U.S. ADVANCE Bridge-to-Transplant (“BTT”) trial, published in the American Heart Association's journal Circulation, reported positive patient outcomes of 140 candidates who were treated with the HeartWare investigational device. It was observed that survival rates and quality of life improved at 180 day following the treatment. Some of the risks associated with the system include infection, bleeding, perioperative right heart failure and stroke.

The HeartWare Ventricular Assist System comprises a small blood pump called HVAD pump, surgical tools and patient accessories, which help a patient’s weak heart to pump blood from the left ventricle into the aorta. About 2,000 HeartWare Ventricular Assist Systems have been implanted in patients globally. The device was cleared in the European Union in 2009 and in Australia in March 2011. Recently, the company revealed 50 clinical sites in the U.S. along with 91 customer sites in 25 nations.

Currently, the HeartWare Ventricular Assist System is not available commercially in the U.S.. The device is the subject of clinical trials in the U.S. for two indications, namely, BTT under continuous access protocol and destination therapy (“DT”). HeartWare submitted a Pre-Market Approval (“PMA”) application with the U.S. Food and Drug Administration (“FDA”) for the BTT indication in December 2010. The PMA includes data from the ADVANCE trial.

FDA's Circulatory System Devices Advisory Committee, in April 2012, announced that the advantages of using the HeartWare Ventricular Assist System outweigh the risks associated with it.

HeartWare makes miniaturized implantable heart pumps, also known as ventricular assist devices, which are used for the treatment of patients at a risk of advanced heart failure. The company competes in the heart devices market with Thoratec Corporation (THOR - Analyst Report) among others.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.66 +6.49%
RF MICRO DE… RFMD 12.44 +5.78%
VASCO DATA… VDSI 14.82 +5.03%
STRATTEC SE… STRT 81.23 +4.27%
PATTERSON-U… PTEN 34.42 +2.62%